BIODEXA PHARMACEUTICALS-ADR (BDRX) Stock Price, Quote, News and Overview
NASDAQ:BDRX - Nasdaq - US59564R8079 - ADR - Currency: USD
BDRX Quote, Performance and Key Statistics
1.55
-0.01 (-0.64%)
The current stock price of BDRX is 1.55 USD. In the past month the price increased by 20.16%. In the past year, price decreased by -95.23%.
BDRX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.39 | 329.14B | ||
| AMGN | AMGEN INC | 14.17 | 150.99B | ||
| GILD | GILEAD SCIENCES INC | 13.33 | 128.61B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1702.9 | 126.96B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.2 | 65.88B | ||
| ARGX | ARGENX SE - ADR | 330.52 | 37.54B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.72B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.39B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.52B | ||
| NTRA | NATERA INC | N/A | 20.79B | ||
| BIIB | BIOGEN INC | 7.22 | 17.39B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.30B |
Related stock screener links
About BDRX
Company Profile
Biodexa Pharmaceuticals Plc is a drug delivery technology company. The company is headquartered in Abingdon, Oxfordshire and currently employs 13 full-time employees. The company went IPO on 2014-12-08. The firm is developing a pipeline of products for the treatment of diseases with unmet medical needs. Its technologies include Biodexa Pharmaceuticals Q-Sphera, MidaCore and MidaSolve. The Q-Sphera technology focuses on long-acting injectables using proprietary three-dimensional (3D) printing technology that encapsulates medicines into bioresorbable polymer microspheres with precision characteristics. The MidaCore technology platform uses ultra-small gold nanoparticle (GNP) drug conjugates. The MidaSolve Nano Inclusion technology solubilizes molecules that have minimal solubility biological potential of Hydrogen (pH), extending available routes of administration, including direct-to-tumor delivery. Its pipeline includes MTX110, MTD201, MTD211 (Schizophrenia, MDD), MTX223, and MTD217.
Company Info
BIODEXA PHARMACEUTICALS-ADR
1 Caspian Point, Caspian Way
Abingdon OXFORDSHIRE GB
Employees: 13
Company Website: https://www.biodexapharma.com/
Investor Relations: http://biodexapharma.com/investors/
Phone: 4401235888300
BIODEXA PHARMACEUTICALS-ADR / BDRX FAQ
What is the stock price of BIODEXA PHARMACEUTICALS-ADR today?
The current stock price of BDRX is 1.55 USD. The price decreased by -0.64% in the last trading session.
What is the ticker symbol for BIODEXA PHARMACEUTICALS-ADR stock?
The exchange symbol of BIODEXA PHARMACEUTICALS-ADR is BDRX and it is listed on the Nasdaq exchange.
On which exchange is BDRX stock listed?
BDRX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for BIODEXA PHARMACEUTICALS-ADR stock?
7 analysts have analysed BDRX and the average price target is 18.36 USD. This implies a price increase of 1084.52% is expected in the next year compared to the current price of 1.55. Check the BIODEXA PHARMACEUTICALS-ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BIODEXA PHARMACEUTICALS-ADR worth?
BIODEXA PHARMACEUTICALS-ADR (BDRX) has a market capitalization of 3.97M USD. This makes BDRX a Nano Cap stock.
How many employees does BIODEXA PHARMACEUTICALS-ADR have?
BIODEXA PHARMACEUTICALS-ADR (BDRX) currently has 13 employees.
What are the support and resistance levels for BIODEXA PHARMACEUTICALS-ADR (BDRX) stock?
BIODEXA PHARMACEUTICALS-ADR (BDRX) has a support level at 1.44 and a resistance level at 1.77. Check the full technical report for a detailed analysis of BDRX support and resistance levels.
Is BIODEXA PHARMACEUTICALS-ADR (BDRX) expected to grow?
The Revenue of BIODEXA PHARMACEUTICALS-ADR (BDRX) is expected to decline by -100% in the next year. Check the estimates tab for more information on the BDRX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy BIODEXA PHARMACEUTICALS-ADR (BDRX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of BDRX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of BDRX, evaluating the profitability, health, valuation and growth aspects
- BIODEXA PHARMACEUTICALS-ADR (BDRX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BIODEXA PHARMACEUTICALS-ADR (BDRX) Sales and EPS estimates to see what analysts future expectations are.
- BIODEXA PHARMACEUTICALS-ADR (BDRX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BIODEXA PHARMACEUTICALS-ADR (BDRX) Insider and Institutional Ownership to learn about the owners and their transactions.
- BIODEXA PHARMACEUTICALS-ADR (BDRX) Stock Chart to make your own analysis
- BIODEXA PHARMACEUTICALS-ADR (BDRX) Latest news and press-releases to stay up to date.
Does BIODEXA PHARMACEUTICALS-ADR (BDRX) stock pay dividends?
BDRX does not pay a dividend.
What is the Price/Earnings (PE) ratio of BIODEXA PHARMACEUTICALS-ADR (BDRX)?
BIODEXA PHARMACEUTICALS-ADR (BDRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-20.62).
What is the Short Interest ratio of BIODEXA PHARMACEUTICALS-ADR (BDRX) stock?
The outstanding short interest for BIODEXA PHARMACEUTICALS-ADR (BDRX) is 2.74% of its float. Check the ownership tab for more information on the BDRX short interest.
BDRX Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to BDRX. When comparing the yearly performance of all stocks, BDRX is a bad performer in the overall market: 98.9% of all stocks are doing better.
BDRX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to BDRX. BDRX may be in some trouble as it scores bad on both profitability and health.
BDRX Financial Highlights
Over the last trailing twelve months BDRX reported a non-GAAP Earnings per Share(EPS) of -20.62. The EPS increased by 98.74% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -48.82% | ||
| ROE | -78.14% | ||
| Debt/Equity | 0.02 |
BDRX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 86% to BDRX. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 80.32% and a revenue growth -100% for BDRX